U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Prostate Adenocarcinoma

MedGen UID:
1716426
•Concept ID:
C5238405
•
Neoplastic Process

Definition

Prostate adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Prostate Adenocarcinoma

Professional guidelines

PubMed

Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma.
Sciarra A, Bosman C, Monti G, Gentile V, Autran Gomez AM, Ciccariello M, Pastore A, Salvatori G, Fattore F, Di Silverio F
J Urol 2004 Nov;172(5 Pt 1):1775-83. doi: 10.1097/01.ju.0000140875.07255.f5. PMID: 15540720
Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors.
Advani SJ, Chung SM, Yan SY, Gillespie GY, Markert JM, Whitley RJ, Roizman B, Weichselbaum RR
Cancer Res 1999 May 1;59(9):2055-8. PMID: 10232586

Recent clinical studies

Etiology

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA
J Urol 2003 Mar;169(3):1143-9. doi: 10.1097/01.ju.0000042162.08938.27. PMID: 12576870

Diagnosis

Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens.
Granchi S, Brocchi S, Bonaccorsi L, Baldi E, Vinci MC, Forti G, Serio M, Maggi M
Prostate 2001 Dec 1;49(4):267-77. doi: 10.1002/pros.10022. PMID: 11746273

Therapy

Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma.
Santisteban M, Pérez-Gracia JL, Ceballos J, Vivas I, García-Foncillas J
Clin Transl Oncol 2008 Jun;10(6):372-4. doi: 10.1007/s12094-008-0214-9. PMID: 18558585
Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.
Cerulli C, Sciarra A, Salvatori G, Di Silverio F
Urology 2004 Dec;64(6):1231.e1-3. doi: 10.1016/j.urology.2004.06.066. PMID: 15596212
Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma.
Sciarra A, Bosman C, Monti G, Gentile V, Autran Gomez AM, Ciccariello M, Pastore A, Salvatori G, Fattore F, Di Silverio F
J Urol 2004 Nov;172(5 Pt 1):1775-83. doi: 10.1097/01.ju.0000140875.07255.f5. PMID: 15540720
Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA
J Urol 2003 Mar;169(3):1143-9. doi: 10.1097/01.ju.0000042162.08938.27. PMID: 12576870

Clinical prediction guides

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA
J Urol 2003 Mar;169(3):1143-9. doi: 10.1097/01.ju.0000042162.08938.27. PMID: 12576870

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...